Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China

Zhejiang Provincial Tongde Hospital45 enrolled

Overview

This study aimed to investigate the effects of the modified 5:2 IF dietary intervention on the Chinese population with overweight or obesity based on a self-controlled clinical trial.

There are fewer studies on the influence of dietary interventions on the Chinese populations with obesity, and the degree of obesity, body fat distribution, dietary pattern and structure, and metabolic status of populations with obesity are different between the Chinese and European populations. The effects of a 5:2 IF dietary intervention on the Chinese population with overweight or obesity are unclear. Therefore, this study aimed to investigate the effects of the modified 5:2 IF dietary intervention on the Chinese population with overweight or obesity based on a self-controlled clinical trial.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Overweight or Obesity

Interventions

A modified 5:2 intermittent fasting dietDIETARY_SUPPLEMENT

The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. participants aged 18 to 60 years 2. participants with a body mass index (BMI) ≥ 24 kg/m2 3. participants engaged in light physical labor and their weight was relatively stable. Exclusion Criteria: 1. participants taking any medication with an effect on body weight in the three months prior to enrollment; 2. participants with liver or kidney dysfunction (liver enzymes ≥ 2 times normal; blood creatinine \> the upper limit of normal); 3. participants with a history of cardiovascular disease (e.g., coronary heart disease, stroke); 4. participants with malignant tumors; 5. women during pregnancy or breastfeeding; 6. participants deemed unsuitable by the investigator to participate in this trial.

Locations (1)

Xiaoli Wang

Hangzhou, China